Evaluation of the diagnostic and prognostic capacity of procalcitonin, C reactive protein, interleukin-6 and lipopolysaccharide binding protein in patients suspected of having sepsis;Evaluación de la capacidad diagnóstica y pronóstica de procalcitonina, proteína C reactiva, interleucina-6 y proteína ligadora del lipopolisacárido en pacientes con sospecha de sepsis

Revista del Laboratorio Clinico

Volumn 3, Issue 1, 2010, Pages 12-19

  Gómez Gerique, Juan Antonio ^a   Ortiz Espejo, María ^a   Torrealba Rodríguez, Mónica Irina ^a   Gordillo Álvarez, Javier ^a   Castellanos Ortega, Álvaro ^a   Suberviola, Borja ^a   Teja, José Luis ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Infection; Procalcitonin; Sepsis; Septic shock; Systemic inflammatory response syndrome

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; PROCALCITONIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; DEATH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 72149095471     PISSN: 18884008     EISSN: 19890389     Source Type: Journal    
DOI: 10.1016/j.labcli.2009.07.003     Document Type: Article

References (25)

1. León Gil C., García-Castrillo Riesgo L., Moya Mir M., Artigas Raventós A., Borges Sa M., and Caudel González F.J. Documento de Consenso (SEMES-SEMICYUC). Recomendaciones del manejo diagnóstico-terapéutico inicial y multidisciplinario de la sepsis grave en los Servicios de Urgencias hospitalarios. Med Intensiva 31 (2007) 375-387
2. Russell J.A. Management of sepsis. N Engl J Med 355 (2006) 1699-1713
3. Martin G.S., Mannino D.M., Eaton S., and Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003) 1546-1554
4. Cohen J., Brun-Buisson C., Torres A., and Jorgensen J. Diagnosis of infection in sepsis: An evidence-based review. Crit Care Med 32 (2004) S466-S494
5. Sprung C.L., Sakr Y., Vicent J.L., Le Gall J.R., Reinhart K., Ranieri V.M., et al. An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence in Acutely Ill Patients (SOAP study). Intensive Care Med 32 (2006) 421-427
6. Esteban A., Frutos-Vivar F., Ferguson N.D., Peñuelas O., Lorente J.A., Gordo F., et al. Sepsis incidente and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med 35 (2007) 1284-1289
7. Campaña sobrevivir a la sepsis. Web médica. Protocolos institucionales [consultado 8/9/2009]. Disponible en: http://www.humv.es/index.php?option=com_docman&task=cat_view&gid=48&Itemid=27
8. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 (2003) 1250-1256
9. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-74.
10. Knaus W.A., Draper E.A., Wagner D.P., and Zimmerman J.E. APACHE II: A severity of disease classification system. Crit Care Med 13 (1985) 818-829
11. Edwards A.T., Ng K.J., Shandall A.A., and Price-Thomas J.M. Experience with the APACHE II severity of disease scoring system in predicting outcome in a surgical intensive therapy unit. J R Coll Surg Edinb 36 (1991) 37-40
12. Garnacho Montero J., and Garnacho Montero C. Polimorfismos del ADN mitocondrial y mortalidad en la sepsis: ¿hemos hallado la aguja en el pajar?. Med Intensiva 31 (2007) 184-186
13. Viallon A., Guyomarc′h S., Marjollet O., Berger C., Carricajo A., and Robert F. Can emergency physicians identify a high mortality subgroup of patients with sepsis: Role of procalcitonin. Eur J Emerg Med 15 (2008) 26-33
14. Mokart D., Merlin M., Sannini A., Brun J.P., Delpero J.R., Houvenaeghel G., et al. Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): Early markers of postoperative sepsis after major surgery. Brit J Anaesth 94 (2005) 767-773
15. Werra I., Jaccard C., Corradin S.B., Chioléro R., Yersin B., Gallati H., et al. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: Comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 25 (1997) 607-613
16. Müller B., Becker K.L., Schächinger H., Rickenbacher P.R., Huber P.R., and Zimmerli W. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 28 (2000) 977-983
17. Nobre V., Harbarth S., Graf J.D., Rohner P., and Pugin J. Uso de determinaciones seriadas de procalcitonina para acortar la duración del tratamiento antibiótico en pacientes con sepsis grave. Am J Respir Crit Care Med 177 (2008) 498-505
18. Uzzan B., Cohen R., Nicolas P., Cucherat M., and Perret G.Y. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis. Crit Care Med 34 (2006) 1996-2003
19. Cheval C, Timsit JF, Garrouste-Orgeas M, Assicot M, De Jonghe B, Misset B. et al. Procalcitonin (PCT) is useful in predicting the bacterial origin of an acute circulatory failure in crytically ill patients. Intensive Care Med. 2000;26 Suppl2: S153-8.
20. Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med. 2000;26 Suppl 2:S148-52.
21. Tang B., Eslick G., Craig J., and McLean A. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: Systematic review and meta-analysis. Lancet Infect Dis 7 (2007) 210-217
22. Thomas-Rudolph D., Du Clos T.W., Snapper C.M., and Mold C. C-reactive protein enhances immunity to Streptococcus pneumoniae by targeting uptake to Fc gamma R on dendritic cells. J Immunol 178 (2007) 7283-7291
23. Mold C., Rodríguez W., Rodic-Polic B., and Du Clos T.W. C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. J Immunol 169 (2002) 7019-7025
24. Tavares E., and Miñano F.J. Procalcitonin N-terminal peptide causes catabolic effects via the hypothalamus and prostaglandin-dependent pathways. Neuroendocrinology 88 (2008) 316-326
25. Sexton P.M., Christopoulos G., Christopoulos A., Nylen E.S., Snider Jr. R.H., and Becker K.L. Procalcitonin has bioactivity at calcitonin receptor family complexes: Potential mediator implications in sepsis. Crit Care Med 36 (2008) 1637-1640